Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 7, 2026Diabetes

At 3 years, the cumulative risk of MACE in the trial-matched group was lower for DPP-4i than SU users (17.0% vs 19.5%) with a risk ratio of 0.87 (95% CI 0.87-0.88, p<0.001).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does DPP-4i reduce 4-point MACE compared to sulfonylurea in people with type 2 diabetes?

Population

416,162 individuals with type 2 diabetes from the UK Clinical Practice Research Datalink, divided into a…

Comparison

Dipeptidyl peptidase-4 inhibitors (DPP-4i) vs Sulfonylurea (SU)

Design

Cohort

Follow-up

3 years

Authors

GMGILBERTE MARTINE-EDITHJTJonah J C ThomasSGSafoora Gharibzadeh

Discussion

Loading...

Member takes

Overview

Real-world data from the UK CPRD suggests DPP-4i treatment is associated with a lower risk of MACE compared to sulfonylureas in patients with type 2 diabetes, with a more pronounced effect in those with pre-existing cardiovascular disease.

Key Points

  • This research aims to evaluate the effects of DPP-4 inhibitors on cardiovascular outcomes in a real-world population with type 2 diabetes.
  • Analyzed 527,381 individuals with type 2 diabetes from the UK CPRD receiving either DPP-4i or sulfonylurea.
  • Matched a subgroup (n=11,987) to TECOS trial criteria and assessed primary outcome of 4-point MACE after 3 years.
  • Applied longitudinal targeted maximum likelihood estimation for association analysis.
  • In the trial-matched group, MACE risk was significantly lower for DPP-4i users (17.0%) compared to sulfonylurea users (19.5%) with a risk ratio of 0.87 (95% CI 0.87-0.88, p<0.001).
  • Unmatched group showed non-significant MACE risk difference between DPP-4i (5.5%) and sulfonylurea (5.7%) users (RR 0.96, p<0.001).
  • The impact of DPP-4i on MACE risk appears less pronounced in the unmatched group.

Structured PICO

Does DPP-4i reduce 4-point MACE compared to sulfonylurea in people with type 2 diabetes?

P
Population
416,162 individuals with type 2 diabetes from the UK Clinical Practice Research Datalink (CPRD), divided into a TECOS trial-matched group (n=11,987; aged ≥50 years, HbA1c 48-64 mmol/mol, pre-existing cardiovascular disease) and an unmatched group (n=404,175).
I
Intervention
Dipeptidyl peptidase-4 inhibitors (DPP-4i)
C
Comparator
Sulfonylurea (SU)
O
Outcome
4-point MACE 3 years after treatment initiationcomposite

Real-world data from the UK CPRD suggests DPP-4i treatment is associated with a lower risk of MACE compared to sulfonylureas in patients with type 2 diabetes, with a more pronounced effect in those with pre-existing cardiovascular disease.

Cite This Study

MARTINE-EDITH et al. (2026) studied this question.

synapsesocial.com/papers/6a250c507def13d035e1c61ehttps://doi.org/10.2337/db26-1824-p
View Full Paper
Ask AI
Bookmark
Share